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ABSTRACT: The pathophysiology of arteriovenous fistula (AVF) maturation failure is not completely un-
derstood but impaired outward remodeling (OR) and intimal hyperplasia are thought to be contributors. This
adverse vascular response after AVF surgery results from interplay between vascular smooth muscle cells
(VSMCs), the extracellular matrix (ECM), and inflammatory cells. Relaxin (RLN) is a hormone that acts on the
vasculature via interaction with RLN/insulin-like peptide family receptor 1 (RXFP1), resulting in vasodilata-
tion, ECM remodeling, and decreased inflammation. In the present study, we evaluated the consequences of
RXFP1knockout (Rxfp12/2) onAVFmaturation in amurinemodel ofAVF failure.Rxfp12/2mice showeda 22%
decrease in vessel size at the venous outflow tract 14 d afterAVF surgery. Furthermore, a 43% increase in elastin
contentwas observed in the lesions ofRxfp12/2mice and coincidedwith a 41% reduction in elastase activity. In
addition, Rxfp12/2 mice displayed a 6-fold increase in CD45+ leukocytes, along with a 2-fold increase in
monocyte chemoattractant protein 1 (MCP1) levels, when compared with wild-type mice. In vitro, VSMCs
from Rxfp12/2mice exhibited a synthetic phenotype, as illustrated by augmentation of collagen, fibronectin,
TGF-b, and platelet-derived growth factor mRNA. In addition, VSMCs derived from Rxfp12/2mice showed a
5-fold increase in cell migration. Finally, RXFP1 and RLN expression levels were increased in human AVFs
when comparedwith unoperated cephalic veins. In conclusion, RXFP1deficiency hampers elastin degradation
and results in induced vascular inflammation after AVF surgery. These processes impair OR in murine AVF,
suggesting that theRLNaxis couldbeapotential therapeutic target forpromotingAVFmaturation.—Bezhaeva,T.,de
Vries,M.R.,Geelhoed,W. J., vanderVeer,E. P.,Versteeg, S., vanAlem,C.M.A.,Voorzaat,B.M., Eijkelkamp,N., van
der Bogt, K. E., Agoulnik, A. I., van Zonneveld, A.-J., Quax, P. H. A., Rotmans, J. I. Relaxin receptor
deficiency promotes vascular inflammation and impairs outward remodeling in arteriovenous fistulas.
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A properly functioning vascular access site is a crucial
lifeline for patients required to undergo hemodialysis.
Although an arteriovenous fistula (AVF) remains the
vascular access of choice, the frequency of primary AVF
failure is ;40% (1). Moreover, the primary patency rates
1 yr after creation do not exceed 60% (2), making vascular
access–related complications one of the most common
causes of hospitalization and morbidity in hemodialysis
patients.
Although the pathophysiology of AVF maturation
failure is incompletely understood, it is well established
thatboth intimalhyperplasia (IH)andoutwardremodeling
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(OR) of the arteriovenous conduit ultimately determine
luminal dimensions, fistula flow andpatency (3). Several
studies have shown that vascular adaptation of the ar-
teriovenous conduit is characterized by an inflammatory
response that coincides with flow-mediated remodeling
of the extracellular matrix (ECM) and proliferation and
migration of vascular smooth muscle cells (VSMCs)
(4–11).
Relaxin (RLN) is a 6-kDa peptide hormone, originally
known for its role in the growth and differentiation of the
reproductive tract, and systemic hemodynamic adap-
tations during pregnancy, in particular vasodilatation
(12–15). Three RLN genes, namely RLN1, 2, and 3, exist in
humans, whereas rats and mice have 2 (Rln1 and 3), with
Rln1 in rats and mice corresponding to human RLN2 and
representing the primary source of circulating RLN (16). In
the last 20 yr, RLN has emerged as a pleiotropic hormone
that serves critical functions irrespective of gender. The
systemic effects mediated by RLN2 on arterial mechanical
properties include increasing arterial compliance, reducing
systemic vascular resistance, and myogenic reactivity as
demonstrated in rats and mice (12, 17–20). Furthermore,
administrationof recombinantRLN2ameliorates renal and
cardiac fibrosis, stimulates ECM turnover, and moderates
inflammationby reducing inflammatory cytokines (21–27).
In the context of AVF maturation, it is important to
emphasize that RLN2 is expressed in the vessel wall (28,
29) and that the observed vascular effects of RLN2 are
mediated though an interaction with RLN/insulin-like
peptide family receptor 1 (RXFP1), a G-protein–coupled
receptor.RXFP1 isprimarily expressedonVSMCsand to a
lesser extent on the cell surface of macrophages and en-
dothelial cells of arteries and veins (30–32).
In light of the emerging role of the RLN2-RXFP1 axis in
vascular remodeling and inflammation, we examined the
consequences of disturbing this hormone–receptor bal-
ance inAVFmaturation. For this purpose,we used awell-
established murine AVF model to study the effect of
RXFP1 deficiency on fistula remodeling. Furthermore, we
determined the effects of RXFP1 deficiency on the phe-
notype and function of VSMCs in vitro.
MATERIALS AND METHODS
Animals
This studywas performed in agreementwithDutch government
guidelines and Directive 2010/63/EU of the European Parlia-
ment.All animal experimentswere approvedby the Institutional
Committee for Animal Welfare of both Leiden University Med-
ical Center and University Medical Center Utrecht. The pheno-
type of Rxfp12/2mice has been previously described (33). Male
wild-type (WT, C57BL/6, n = 10) and Rxfp12/2mice (C57BL/6,
n = 10), were bred in the animal facility at theUniversityMedical
Center Utrecht. All animals were given water and chow ad
libitum. Adult male mice aged 10–13 wk were used for the ex-
periments. AVFs were created in an end-to-side manner between
the dorsomedial branch of the external jugular vein and the
common carotid artery as previously described (5, 34). Briefly,
the animalwas anesthetizedusing isoflurane before the skin of the
ventralneckareawasshavedanddisinfected.Themousewas then
fixed in a supine position on a heating blanket and injected with
buprenorphin (0.1 mg/kg; MSD, Kenilworth, NJ, USA) and
0.5 ml saline. Under a dissecting microscope (Leica, Wetzlar,
Germany), an incision in the ventral midline of the neck area
was made, followed by a dissection of the right dorsomedial
branch of the external jugular vein and ipsilateral common
carotid artery after the excision of the sternocleidomastoid
muscle using a heat cauterizer. Next, after applying a vascular
clamp (S&T, Neuhausen, Switzerland) on the proximal and
distal artery, an incision (;1 mm) was made using micro-
scissors (Fine Science Tools, North Vancouver, BC, Canada)
and the lumen was rinsed with heparin solution (100 IU/ml;
LEO Pharma, Madison, NJ, USA). The vein was then clamped
proximally, ligated distally, and transected just proximal to the
ligation. After rinsing the vein with heparin solution, an end-to-
side anastomosis was created using 10-0 interrupted sutures
(B. Braun, Bethlehem, PA, USA). After completion of the anasto-
mosis, the remaining clamps were removed and patency was
assessed. The neck incisionwas closedwith a 6-0 running suture (B.
Braun). Following completion of the surgery, 0.5 ml of saline was
injectedsubcutaneouslyandthemicewerekeptwarmuntil recovery.
The animals were euthanized 14 d after the surgical procedure.
Blood pressure
Systolic blood pressure was assessed with the noninvasive tail
cuff system in consciousmice before the AVF surgery and on d 7
and 14 after an AVF was created using the CODA system (Kent
Scientific, Torrington, CT, USA). Animals were acclimated to the
restrainer before measurements. Following the acclimation pe-
riod, telemetry blood pressure measurements were acquired.
Data segments (10 s each) were collected throughout each non-
invasivemeasurement session (10 acclimation cycles followedby
20 measurement cycles).
Arterial compliance
Aortas from Rxfp12/2 (n = 3) andWT (n = 5) mice were cannu-
lated from the distal side at the base of the heart proximal to
the abdominal area (1 cm in length) and placed immediately
in ice-cold 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES)-buffered physiologic saline solution. The vessels were
subsequently placed in an ex vivo vessel perfusion system con-
taining 37°C 1024Mpapaverine in calcium-freeHEPES-buffered
physiologic saline solution. The vessel segments were tensioned
to a longitudinal strain of 30 g and left to acclimatize for 15 min.
The vessel segment was then exposed to a pressurized, cyclic
flow at a rate of 60 6 5 BPM, and the systolic pressure was
gradually increased to 120 mmHg. Papaverine (1024 M) in
calcium-free HEPES-buffered PBS was used as perfusate. The
systolic and diastolic pressures throughout the test were recor-
dedusingapressure sensor (700GPrecisionPressureTestGauge;
Fluke, Everett, WA, USA). To measure vessel diameter, a mi-
croscope camera (Digital Microscope DSCO-P03; Cider House
ICT, EndeavourHills, VIC,Australia) capable ofmeasuringwith
an accuracy of60.02mmwas placed above the perfused vessels.
Recordingsof each testwerecalibrated to thepressureand saved.
To calculate arterial compliance, vessel diameter was measured
during both the systolic and the diastolic phase of each pressure
cycle. The dynamic compliance is provided as percentage com-
pliance per 100 mmHg.
Tissue harvesting and processing
The animals were anesthetized using isoflurane 14 d after AVF
surgery. The venous and arterial limb of the AVF was dissected
and a thoracotomywas performedwhereupon the inferior vena
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cava was transected followed by a fixation with 4% formalin
through an intracardiac perfusion. The tissue was embedded in
paraffin and 5 mm sections of the venous outflow tract were cut
perpendicular to the vein at intervals of 150 mm.
Morphometric and histologic analysis
All immunohistochemical and histochemical staining and mea-
surements were performed on the first 3 venous cross-sections
downstream from the anastomosis. Weigert’s elastin stain was
used for the morphometric measurements. The area of the in-
ternal elastic lamina (IEL) was measured to assess the degree of
OR (Fig. 1A). IH was calculated by subtracting the luminal area
fromtheareawithin the IEL.Compositionof theAVF lesionswas
further evaluated by staining for total leukocytes (CD45, 1:200;
550539; BD Biosciences, Franklin Lakes, NJ, USA) and macro-
phages [macrophage marker (MAC3), 1:200, 550292; BD Biosci-
ences] in combination with CCR2 (chemokine receptor type 2)
for a proinflammatory phenotype (1:400; ab32144; Abcam,
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Figure 1.Morphometry and histology of the venous outﬂow tract of the AVF in Rxfp12/2 and WT mice 14 d after surgery. A) The
area within the IEL (red) reﬂects the degree of OR of the venous outﬂow tract. IH (green) was calculated by subtracting the
luminal area (blue) from the area within the IEL. B) Western blot of the jugular vein conﬁrms the absence of RXFP1 protein in
RXFP1-deﬁcient mice. GAPDH was used as a loading control. C) Quantiﬁcation of histomorphometry. RXFP1-deﬁcient mice
displayed decrease in the area of IEL (22%, P = 0.002) and lumen (31%, P = 0.14), whereas IH was comparable to that of WT
mice. D) Increase in elastin deposition in the AVF lesions from Rxfp12/2 mice. E) aSMA staining shows area of IH which did not
differ between the groups. Weigert elastine staining was used to determine histomorphometrical parameters of the vessel. *P ,
0.05; **P , 0.005 (n = 10/group).
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Cambridge, United Kingdom) or CD206 (1:1000, ab64693;
Abcam) for an anti-inflammatory phenotype, neutrophils
[granulocytic marker (GR1), 1:300; fromG. Kraal, VUUniversity
Medical Center, Amsterdam, The Netherlands], T-lymphocytes
(CD3, 1:300, ab32144; Abcam), and monocyte chemoattractant
protein 1 (MCP1, 1:300, sc-1784; Santa Cruz Biotechnology,
Dallas, TX, USA). VSMCs [SM-a-actin (aSMA), 1:1000, M0851;
Agilent Technologies, Santa Clara, CA, USA] were stained in a
combination with Ki67 (1:200, 550609; BD Biosciences) to detect
proliferating VSMCs.
All slides were digitized using an automated slide scanner
(Pannoramic MIDI; 3DHistech, Budapest, Hungary). For the
immunohistochemical analysis of the MAC3/CD206, MAC3/
CCR2, and aSMA/Ki67 staining, the number of positive cells
was counted in 3 random fields of view at 3400 magnification,
from which the mean was calculated. Quantification of CD45+,
GR1+, CD3+, and MCP1 staining was performed with ImageJ
software (National Institutes of Health, Bethesda, MD, USA) by
calculating percentage of 3,39-diaminobenzidine (DAB) positive
area from the total vessel area.
Cell culture
Primary arterial and venous VSMCs were isolated from the ca-
rotidarteryandvenacavaofC57BL/6andRxfp12/2mice (n=4/
group), respectively. Connective tissues were removed and
vessels cut open. The endothelial monolayer was detached by
gently scraping with sterile surgical forceps. The carotid artery
and caval vein were dissected into small pieces and plated onto
fibronectin-coated Petri dishes (0.1 mg/ml) 100 or 60 mm in di-
ameter. After a 14 d culture in DMEM supplemented with 20%
fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin, cells were trypsinized and replated
onto 6- or 12-well plates and cultured for 7 d. At 80–90% con-
fluence, VSMCs were trypsinized and seeded at the required
density for further functional assays.
Western blot
Proteins from tissue lysates were harvested in RIPA buffer and
subjected toSDS-PAGE.Abicinchronic acidassaywasperformed
to ensure equal protein loads in each sample.RXFP1wasdetected
using primary antibodies (1:500, AP23446SU-S; OriGene Tech-
nologies, Rockville, MD, USA). Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH; 1:5000, 5174S, Cell Signaling Technology,
Danvers, MA, USA) was used as a loading control. All tests used
Bio-Rad TGX precast gels and were blotted on nitrocellulose
0.2mmusing the Bio-RadTurboBlot system (Hercules, CA,USA).
RNA isolation, cDNA synthesis and quantitative
RT-PCR
Total RNA was extracted from VSMCs using Trizol reagent
(Thermo Fisher Scientific) according to the manufacturer’s pro-
tocol. RNA was reverse transcribed using the M-MLV First-
Strand Synthesis System (Thermo Fisher Scientific) and used for
quantitative analysis of mouse genes (Supplemental Table 1)
with SYBRGreenMaster Mix (Thermo Fisher Scientific). Murine
b-actinwasusedas the standardhousekeepinggene.The relative
mRNAexpression levelswere determined using 22DDCtmethod.
VSMC migration and haptotaxis assays
Primary arterial and venous VSMCs from control and Rxfp12/2
mice were grown to confluence and made quiescent in cultured
medium supplemented with 1% FBS for 24 h. Cells were de-
tached from the surface and suspended at a concentration of
100,000 cells/ml in culture medium supplementedwith 1% FBS.
Migrationwas assayedwith inserts having 8mmpores in 24-well
chemotaxis chambers using the CytoSelect Cell Migration Assay
Kit (Cell Biolabs, San Diego, CA, USA). Haptotaxis was assayed
by plating cells into Transwell inserts with collagen I-coated in-
serts (CytoSelect Cell Haptotaxis Assay; Cell Biolabs). After 16 h,
migratory VSMCs were lysed and labeled with fluorescent dye
according to the manufacturer’s instructions. A gradient of 20%
FBS was used. Quantification was performed by reading fluo-
rescence at 480/520 nm.
VSMC proliferation assay
Murine VSMCs, explanted from aortas and veins of control or
Rxfp12/2 mice, were cultured as described in the previous sec-
tion, divided into aliquots, and plated on a 96-well plate. Cells
were quantified 24 h later using the CyQuant Direct Cell Pro-
liferation Assay according to the manufacturer’s instructions
(Thermo Fisher Scientific).
Elastase activity assay
Elastase activity was measured on total tissue lysates isolated
from Rxfp12/2 and WT mice (n = 10 per group) using the Enz-
Chek Assay Kit (Thermo Fisher Scientific) according to the
manufacturer’s instructions. Briefly, 10mmsections ofAVFwere
lysed in RIPA buffer and a bicinchoninic acid assay was per-
formed to ensure equal loading of protein in each sample. DQ
elastin, a soluble bovine neck ligament elastin labeled with
BODIPY FL dye (Thermo Fisher Scientific), was used as a sub-
strate to quench the conjugate’s fluorescence. In the presence of
elastase, the nonfluorescent substrate is digested, yielding highly
fluorescent fragments, which were measured with a microplate
reader at an excitation wavelength of 480 6 20 nm and an
emission wavelength of 5286 20 nm.
Collagen assay
Collagen content was analyzed using the QuickZyme Total
Collagen Assay Kit (QuickZyme Biosciences, Leiden, The Neth-
erlands) on samples of formaldehyde-fixed, paraffin-embedded
venous tissues isolated from Rxfp12/2 andWTmice (n = 10 per
group). In brief, 5–10 tissue sections (10 mm long) were hydro-
lyzed by overnight incubation at 95°C in a heat block. Upon
hydrolysis, without any pretreatment, 35 ml was used for colla-
gen quantification using the QuickZyme Total Collagen Assay
Kit (assay time 90 min). The assay measured the total amount of
hydroxyproline, a representative for all collagen types, present in
the sample. The assay results in a chromogen with a maximum
absorbance of 570 nm.
Human tissue specimens
Human cephalic veins before AVF surgery (n = 3) and during
surgical revisions of AVF (n = 3) were obtained at the Leiden
University Medical Center in accordance with guidelines set out
by theCode forProper SecondaryUseofHumanTissueenforced
by the Dutch Federation of Biomedical Scientific Societies, which
conform to the principles outlined in the Declaration of Helsinki.
Specimens were fixed with formalin, embedded in paraffin, and
sectioned. The human AVF sections were stained with aSMA
(1:1000; M0851; Agilent Technologies), RLX2 (RLN2, 1:1000,
ab183505; Abcam), and RXFP1 (1:4000, AP23446SU-S; OriGene
Technologies).
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ForRXFP1antibodyvalidation, 3human fistula sampleswere
incubated with the primary antibody or isotype control, both at
1:4000 dilution. Human endometrium was used as a positive
control. Briefly, after deparaffinization step endogenous peroxi-
dase was suppressed by incubation in 1% H2O2 for 15 min at
room temperature. Sections were then blocked with 5% PBSA
(NaPO4, NaCl, NaAz and 1% bovine serum albumin) and 5%
normal human serum (NHS) for 30 min. Next, sections were
incubated overnight at room temperature with the primary an-
tibody or isotype control, diluted at 1:4000, in 1% PBS buffer
without calcium and magnesium, supplemented with 5% NHS.
After rinsing in PBS for 3 cycles of 5 min each, sections were
incubatedwith rabbitEvision (Agilent) and5%NHSfor30minat
room temperature. Specific signals were detected using DAB
(MilliporeSigma, Burlington, MA, USA) as chromogen. The re-
action was halted by rapidly rinsing the sections in tap water
before subjecting tissue samples to conventional hemalaun
counterstaining.
For immunofluorescent staining of double-positive aSMA+
and RXFP1+ cells, after exposure to primary antibodies, tissue
sections were counterstained with Alexa 568–conjugated goat
antimouse IgG2a (1:250; A21134;Molecular Probes, Eugene, OR,
USA) for aSMA, and Alexa 488–conjugated secondary goat
antirabbit IgG (1:250; A11008; Molecular Probes) for RXFP1.
Secondary antibodies were diluted in 1% PBSA; 5% NHS was
added to prevent nonspecific binding. Nuclei were visualized
with ProLong Gold Antifade Mountant with DAPI (P369;
Thermo Fisher Scientific) (Supplemental Fig. 6).
Statistical analysis
Results are expressedasmeans6 SEMandvaluesofP,0.05were
considered statistically significant. Student’s t tests and the
Mann–Whitney U tests for parametric and nonparametric data,
respectively, were used as appropriate. For all in vitro experi-
ments, 4 samples from different animals were used (biological
n 5 4). Every experiment within each animal was performed in
triplicates (experimental triplicate n5 3).
RESULTS
Surgical outcome and patency
In total, AVF surgery was successfully performed on
23 mice (WT: n = 12; Rxfp12/2: n = 11), of which 2 (17%)
from the WT group and 1 (9%) from the Rxfp12/2group
were occluded 14 d after surgery. The occluded AVFs
were excluded from morphometric analysis, yielding 10
animals/group. The body weight of the mice was similar
in bothgroups (296 3g) and remained stable until the end
of experiment.
Effect of RXFP1 deficiency on AVF maturation
To study the effect of RXFP1 deficiency on AVF matura-
tion,we createdAVFs inWTandRxfp12/2mice inan end-
to-side fashion between the jugular vein andcarotid artery
as previously described (34). Given that most of the ste-
notic lesions in human AVFs occur in the venous outflow
tract, we harvested the first 3 consecutive venous sections
downstream of the anastomotic area for morphometric
analysis. The impact of RXFP1 deficiency on vessel mor-
phometry was evaluated by assessing both intimal and
luminal area as well as the area within the IEL, reflecting
the degree of OR of the venous outflow tract (Fig. 1A). The
absence of the RXFP1 protein in Rxfp12/2mice was con-
firmedbyusingWestern blot to analyze total tissue lysates
isolated from jugular veins (Fig. 1B). Mice deficient in
RXFP1 showed a 22% decrease of the IEL area at the ve-
nous outflow tract when compared with WT mice (P =
0.002). The luminal area of the venous outflow tract in
Rxfp12/2 mice was 31% smaller when compared with
control mice, although this difference was not significant
(P = 0.14). The intimal area did not differ between groups
(Fig. 1C). Arterial blood pressure and compliance did
not significantly differ between Rxfp12/2 and WT mice
(Supplemental Fig. 1).
In terms of ECM remodeling, we observed a 43% in-
crease in elastin content in Rxfp12/2mice over that ofWT
mice (P=0.04) (Fig. 1D),whereas collagen productionwas
similar in both groups (Supplemental Fig. 2). In both WT
andRxfp12/2mice, themajority of intimal cells expressed
aSMA, indicating that these cells areprimarily ofVSMCor
fibroblastic origin (Fig. 1E).
RXFP1 deficiency resulted in increased
inflammation of AVF lesions
Immunohistochemical analysis of sections obtained from
the venous outflow tract showed a 6-fold increase in the
number of CD45+ leukocytes in lesions of Rxfp12/2mice
when compared with WT mice (P = 0.02) (Fig. 2A). As
shown in Fig. 2B, C, further characterization of the leuko-
cyte subpopulations revealed a 4-fold increase in the
number of proinflammatoryMac3+/CCR2+macrophages
(P = 0.02) and a 43% increase in the Mac3+/CD206+ anti-
inflammatory macrophages in the lesions from Rxfp12/2
mice (P = 0.04). The number of GR1+ neutrophils was
3-fold higher in Rxfp12/2mice than inWTmice (P = 0.05)
(Fig. 2D). The number of CD3+ T-lymphocytes in the
venousoutflow tractwasnot affectedbyRXFP1deficiency
(Supplemental Fig. 3). At the level of cytokine production
within the lesions, MCP1 expression was 2-fold greater in
Rxfp12/2mice than in WT mice (P = 0.01) (Fig. 3).
In vitro, activatedmacrophages thatwere differentiated
frommonocytes derived from Rxfp12/2mice produced a
similar amount of cytokines as WT mice did; ELISA
analysis demonstrated comparable expression of MCP1,
IL12, and IL10 proteins (data not shown).
Phenotypic switch of arterial and venous
VSMCs upon RXFP1 deletion
The impact of RXFP1 deficiency on the VSMC phenotype
was studied in vitro using primary arterial and venous
VSMCs isolated from the aorta and caval vein, re-
spectively, ofRxfp12/2orWTmice. Phenotypic difference
of arterial and venous VSMCs was confirmed by mRNA
levels of ephrin B2, an established embryological marker
of arterial origin (35). EphrinB2 was increased in arterial
VSMCs from bothWT andRxfp12/2mice following 2wk
of culture, but not in venous VSMCs (Fig. 4A). Further
characterization of these VSMCs confirmed that the cells
RELAXIN RECEPTOR DEFICIENCY IMPAIRS VENOUS OUTWARD REMODELING 6297
Downloaded from www.fasebj.org by Leids Univ Medisch Centrum Walaeus Bibl C1-Q (145.88.209.33) on July 22, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 6293-6304.
maintained a highly differentiated state, as evidenced by
the maintenance of myosin heavy chain, calponin, and
caldesmon expression at 2 wk of culture (Fig. 4B).
Because vascular injury and remodeling trigger the
phenotypic switch of VSMCs from a contractile to a syn-
thetic state, mRNA expression levels of several genes as-
sociated with this switch were measured (36, 37). Arterial
VSMCs from Rxfp12/2 mice expressed markedly higher
levels of the synthetic VSMC markers type I collagen (38)
and fibronectin (39) than did VSMCs derived from WT
mice [5-fold (P = 0.03) and 10-fold (P = 0.04), respectively].
Similarly, the mRNA expression levels of both type I col-
lagen and fibronectin were higher in venous VSMCs har-
vested fromRxfp12/2mice [3-fold (P=0.05) and4-fold (P=
0.04), respectively]. Furthermore, genes linked with cellu-
lar proliferation, such as TGF-b1 (40) and platelet-derived
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Figure 2. Effects of RXFP1 deﬁciency on inﬂammatory status in vivo. Quantiﬁcation and immunohistochemical staining of CD45+
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growth factor (41), displayed on average 3-fold higher
expression levels in both arterial and venous VSMCs iso-
lated from Rxfp12/2mice than did WTmice (Fig. 4C).
To further examine whether RLN deficiency impacts
VSMC function, we performed cellular migration assays.
These studies revealed that arterial VSMCs derived from
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Figure 3. Accumulation of MCP1 in the AVF lesions from Rxfp12/2 and WT mice 14 d after surgery. RXFP1 deﬁciency resulted in
greater MCP1 expression (brown DAB signal) than that found in WT mice. *P , 0.05 (n = 10/group).
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expression of myosin heavy chain, calponin, and caldesmon genes. C) RXFP1 deﬁciency resulted in a switch of arterial and
venous VSMCs to a synthetic phenotype as conﬁrmed by increased collagen I (Col1), ﬁbronectine, TGF-b, and platelet-derived
growth factor mRNA expression levels. VSMCs were maintained in culture for 14 d. *P, 0.05, **P, 0.005, ****P, 0.0001 (n = 4).
RELAXIN RECEPTOR DEFICIENCY IMPAIRS VENOUS OUTWARD REMODELING 6299
Downloaded from www.fasebj.org by Leids Univ Medisch Centrum Walaeus Bibl C1-Q (145.88.209.33) on July 22, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 6293-6304.
Rxfp12/2displayasignificantlyhighermigratory capacity
relative to VSMCs derived from WT mice, whereas mi-
gration of venous VSMCs was unaltered (Fig. 5A). To
mimic VSMCmigrationwithin the ECMof a blood vessel,
a haptotaxis assay was performed to evaluate cellular
migration in a matrix of type I collagen. As shown in Fig.
5B, we observed enhanced migration of arterial and ve-
nous VSMCs derived from Rxfp12/2 mice when com-
pared with WT [5-fold (P = 0.05) and 5-fold (P = 0.03),
respectively]. In contrast, cellular proliferation was not
affected by RLN deficiency in either arterial or venous
VSMCs (Fig. 5C). In vivo, the number of proliferating cells
in the venous outflow tract of AVF did not differ signifi-
cantly between groups (Supplemental Fig. 4).
Elastin metabolism in AVF lesions of
RXFP1-deficient mice
Having observed higher elastin content in the venous
outflow tract of AVF in Rxfp12/2mice, we next assessed
elastase activity in sections obtained from the venous
outflow tract of the AVF. We employed the EnzChek as-
say, whichmeasures fluorescence of the substrate (bovine
elastin) digested by elastase. Elastase activity was signifi-
cantly lower in AVFs from Rxfp12/2 mice than in AVFs
derived fromWTmice (P = 0.0001) (Fig. 6).
Exvivo, elastin synthesis in cultured arterial andvenous
VSMCs isolated from Rxfp12/2 orWTmice did not differ
because mRNA expression levels of tropoelastin were
similar between the groups (Supplemental Fig. 5).
In humans RXFP1 expression increases during
AVF maturation
To explore the relevance of our observations for dialysis
patients, we examined 3 specimens of cephalic vein before
AVF surgery and during surgical revisions of AVF. Im-
munohistochemical analysis revealed increased RLN2
and RXFP1 expression in the cephalic outflow tract of
AVF, when compared with segments of cephalic veins
from patients with end-stage renal failure during primary
AVF surgery (Fig. 7A). Cells that expressed RLN2
and RXFP1 were enriched in the intimal region of the
outflow tract and were found to coexpress aSMA
(Fig. 7B). These results strongly suggest that RLN2 and
RXFP1 expression is elevated in the venous outflow
tract of humanAVFs, which underscores the relevance
of these proteins in the process of AVF maturation in
humans.
DISCUSSION
Here, we show that although RXFP1 deficiency sub-
stantially impairs OR in amurine model of AVF, no effect
on IH is observed. Our findings pinpoint an increase in
elastin content in the venous outflow tract in RXFP1-
deficientmice linkedwith attenuated elastase activity as a
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potential cause for this phenotype. As such, impaired
elastin degradation in combination with enhanced vas-
cular inflammation after AVF surgery likely triggers
adverse vascular response in humans following the
placement of an AVF.
Impaired elastin degradation and vascular
remodeling in RXFP1-deficient mice
Expansion of the venous lumen and an initial vasodilatory
response are prerequisites for successful AVF maturation
andpatency. Inparticular, theprocessofORplaysapivotal
role in this process. Although past research has focused
mainly on the development of strategies to reduce IH, the
current view on AVF maturation underscores the link be-
tween impaired OR and AVF failure (42, 43). To promote
OR, matrix metalloproteinase expression must be aug-
mented todegradeandrestructure thevascularmatrix (44),
which is largely composed of elastic fibers. Interestingly,
periadventitial application of recombinant elastase has
been shown to stimulate OR in a rabbitmodel of AVF (45).
Interestingly, this concept of pharmacological elastin deg-
radation to promote AVF maturation is now being evalu-
ated in phase III clinical trials (46).
Enhanced expression of RLN is critical for ECM
remodeling in the cervix and myometrium during preg-
nancy (47, 48). Administration of recombinant RLN in-
creases the activity of elastase in human myometrial cells
(26). Our discovery that RXFP1 deficiency significantly
reduced elastase activity, resulting in elastic fiber accu-
mulation in AVF lesions, suggests that RXFP1 is an im-
portant regulator of elastin degradation during AVF
maturation. Furthermore, it supports the concept that
Figure 7. Expression of RLN2 and RXFP1 proteins by aSMA+ cells in dialysis patients. A) Representative images of RLN2 and
RXFP1 proteins (black arrows) in human cephalic veins prior to AVF surgery and cephalic venous outﬂow tract from AVF. B)
Cells positive for RLN2 and RXFP1 (green) were mainly located in the intimal region and were coexpressing aSMA (red); n = 3.
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venous OR requires RLN axis–mediated augmentation of
elastase activity.
RXFP1 deficiency enhances vascular
inflammation after AVF surgery
Successful AVF maturation is severely hampered by ex-
cessive postsurgical inflammation. Numerous animal
studies have shown that drivers of inflammatory re-
sponses, such as hemeoxygenase-1 and -2 (HO-1 andHO-
2) andMCP1, are linked toAVF failure (49–51).Within the
AVF, MCP1 has been found to enhance monocyte re-
cruitment and macrophage differentiation, activate en-
dothelial cells, and stimulate VSMC proliferation (51). In
one of our previous studies, local administration of lipo-
somal prednisolone resulted in a reduction of the in-
flammatory response that subsequently led to a sharp
increase in venous OR in a murine model of AVF (4). In-
terestingly, RLN–RLN receptor interactions are known to
mitigate vascular inflammation by inhibiting the up-
regulation of proinflammatory cytokines (27). In keeping
with these findings, we found that RXFP1 deficiency
augments vascular inflammation in AVFs, illustrated by a
significant increase in macrophages and neutrophils as
well as accumulation ofMCP1 in the venous outflow tract.
Phenotypic switch of VSMCs from RXFP12/2 in
vitro does not influence IH in vivo
In anunexpected turn of events,wedid not observe effects
on venous IH, despite elevated levels of MCP1 in AVF
lesions of Rxfp12/2mice. To unravel this observation, we
conducted in vitro studies on VSMCs, which play a key
role in IH formation and AVF maturation. We observed
that RXFP1 ablation caused a phenotypic switch of both
arterial and venous VSMCs from a contractile to a syn-
thetic phenotype. The switch from the contractile pheno-
type to the synthetic is associatedwith increasedmigratory
and proliferative capacity. Indeed, functional studies
revealed an increase in migration of arterial cells from
RXFP12/2micewhereasmigrationof venous cellswas not
altered. Surprisingly, when cells had to migrate through a
layer of collagen, both arterial and venous VSMCs isolated
form Rxfp12/2 mice displayed elevated migration. Col-
lectively, these findings suggest that the surrounding and
ECM architecture will ultimately determine VSMCs be-
havior and could potentially differ between arterial and
venous VSMCs. It is unclear why RXFP1 deficiency in vivo
resulted in decreased OR and had no effect on IHwhereas
in vitro functional studies clearly show the impact ofRXFP1
deficiency on VSMCs migration. In this respect, it’s im-
portant to notice that the efficacy of cell migration in vivo
strongly depends on the balance between cell deform-
ability andECMdensity, ofwhich the latter is governed by
the capacity of proteolytic enzymes to degrade matrix
components (52). Interestingly, RXFP1 deficiency resulted
in a significant increase in elastin content as a result of
decreased elastase activity. This preserved elastin density
most likely explains why the increasedmigratory capacity
of RXFP1-deficient VSMCs in vitro did not translate into
enhanced intimahyperplasia in the venous outflow tract of
AVF in Rxfp12/2mice.
Alongside the well-established role for the RLN axis in
pregnancy, the evolutionally conserved expression of
RXFP1 within blood vessels of several mammals in a
gender-independent fashion underscores the importance
of this protein–receptor interaction in the vasculature. Our
data indicate that theRLN2andRXFP1proteinsarehighly
expressed in humanAVF lesions, strongly suggesting that
therapeutic targetingof thispathway in the context ofAVF
maturation could be beneficial. In this respect, it is en-
couraging that clinical trials with serelaxin, a recombinant
form of RLN, have displayed promising effects in the
treatment of heart failure (53). In parallel, small-molecule
agonists of RXFP1 are currently being developed (54).
Despite these advances, some aspects of our study re-
quire further discussion. Our studies were performed on
healthy mice; given that animal responses do not neces-
sarily mimic human pathology, it is critical to remain
cautious in extrapolating results derived from murine
studies to patients with chronic renal failure. Another
limitation of our experimental setup is the inability to
perform flow measurements and cannulations of the
murine AVF, as an adequate blood flow volume and the
cannulability of the AVF are the main characteristics of
functional hemodialysis access. Nevertheless, the present
study demonstrates the functional significance of the
RXFP1 pathway in AVF remodeling, implying that the
RLN2-RXFP1pathway could be a novel therapeutic target
to promote maturation and longevity of AVFs for
hemodialysis.
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